Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOPEX: Long-term Study of DBV712 in Peanut-Allergic Children
NCT03859700Phase 3Completed
- Sponsor
- DBV Technologies
- Start
- Dec 2018
- Primary completion
- May 2025
- Modality
- Transdermal Patches
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of DBV712 Viaskin® in peanut allergy, sponsored by DBV Technologies. Primary endpoint: Percentage of Participants Who Were Treatment Responders at 48 months. Started Dec 2018; status: completed.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03859700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03859700.